Key Takeaways:
Orbis Investment Management disclosed it controls a 5.01% stake in biotechnology firm Genmab A/S, according to a company announcement on Wednesday.
The filing was made under Section 30 of the Danish Capital Markets Act, which requires investors to disclose holdings that cross the 5% threshold of a publicly traded company's share capital and voting rights.
By the numbers, Orbis Investment Management's position amounts to 3,221,620 shares in Genmab as of March 31, 2026. The announcement confirms the investment firm as a major shareholder in the Copenhagen-based company, which is listed on the Nasdaq exchange under the ticker GMAB.
The disclosure of a new, significant stake by a large investment firm like Orbis could increase investor confidence in Genmab. This action may attract other institutional investors and increase trading volume as the market digests the new ownership structure. Stock reaction to the announcement was not immediately available.
The entrance of a major new shareholder provides a vote of confidence in Genmab's strategy and pipeline. Investors will be watching for any further changes in institutional ownership ahead of the company's next earnings report.
This article is for informational purposes only and does not constitute investment advice.
